Detalles de la búsqueda
1.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet;
396(10249): 479-488, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702299
2.
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
Lancet Infect Dis;
2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38614117
3.
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.
Expert Rev Vaccines;
22(1): 662-670, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432025
4.
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Lancet Reg Health West Pac;
34: 100731, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37283969
5.
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Lancet Respir Med;
11(7): 613-623, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898400
6.
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Lancet Reg Health West Pac;
: 100829, 2023 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37360864
7.
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Lancet Infect Dis;
23(11): 1313-1322, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37475116
8.
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial.
Sci Bull (Beijing);
68(20): 2448-2455, 2023 10 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37743201
9.
A novel influenza A (H1N1) vaccine in various age groups.
N Engl J Med;
361(25): 2414-23, 2009 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-19846844
10.
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above.
Expert Rev Vaccines;
21(12): 1843-1849, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36048417
11.
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
Lancet Respir Med;
10(8): 739-748, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605625
12.
Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.
Chin J Cancer;
30(8): 559-64, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21801604
13.
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
Signal Transduct Target Ther;
6(1): 271, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34267185
14.
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.
Chin Med J (Engl);
134(11): 1289-1298, 2021 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33928916
15.
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.
Natl Sci Rev;
8(8): nwab053, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34676098
16.
The immunogenicity in healthy infants and efficiency to prevent mother to child transmission of Hepatitis B virus of a 10µg recombinant yeast-derived Hepatitis B vaccine (Hep-KSC).
Vaccine;
34(24): 2656-62, 2016 05 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27113166
17.
Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults.
Vaccine;
32(29): 3706-12, 2014 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24681228
18.
[Application of gene-based logistic kernel-machine regression model on studies related to the genome-wide association].
Zhonghua Liu Xing Bing Xue Za Zhi;
34(6): 633-6, 2013 Jun.
Artículo
en Zh
| MEDLINE | ID: mdl-24125621
19.
Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants.
PLoS One;
7(5): e37206, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22662137
Resultados
1 -
19
de 19
1
Próxima >
>>